ACADEMIC APPOINTMENTS, PROFESSIONAL POSITIONS, AND HONORS
Positions and Employment:
Community Medicine Internship, University of Colorado Denver (UCD), Denver, CO, 1997-1998
Psychiatry Residency, UCD, Denver, CO, 1998-2002
Attending, Colorado Mental Health Institute at Fort Logan, Denver, CO, 2000-2001
Physician Investigator, Research and Development Service, Denver VAMC, Denver, CO, 2002-2008
Instructor, Department of Psychiatry, Division of Psychopharmacology, UCD, Aurora CO, 2002-2006
Assistant Professor, Department of Psychiatry, Division of Psychopharmacology, UCD, Aurora CO, 2006-present
Associate Training Director, Department of Psychiatry General Residency Program, UCD, Aurora CO, 2008-present
Clinical Director, Behavioral Health and Wellness Program, Department of Psychiatry, UCD, Aurora CO, 2009-present
Other Experience and Professional Memberships:
Member, American Psychiatric Association
Secretary, Treasurer, Colorado Psychiatric Society
Member, National Alliance for the Mentally Ill
Summer Research Fellowship, Wake Forest School of Medicine, 1994
First Place, Medical Student Research Day, An Investigation of the Effect of Propofol on Hippocampal GABA-a Receptor Function Utilizing the Patch Clamp Technique, 1994
Society of Biological Psychiatry Eli Lilly Travel Fellowship Award, 2002
Distinguished Laughlin Fellow for professional achievement, dedication and scholarship in psychiatric residency, 2002
American Psychiatric Association-Lilly Resident Research Award, 2003
UCD Department of Psychiatry Junior Faculty Poster Session, Best Poster, 2004
American Association of Chairs of Departments of Psychiatry Faculty Development Award in Psychopharmacology, 2005
Steele Award for Excellence in Teaching (UCD Department of Psychiatry), 2006
Graduate Students: Lecture, “Schizophrenia, Bipolar Disorder and Measures of Inhibition,” Colorado State University Neurosciences Program, 2003; Lecture, “The Lowdown and Highlights of Bipolar Disorder,” 2004, 2006, 2008 NRSC 7614 - Neurobiological Basis of Neuropsychiatric Disorders, UC Denver
Psychiatry Residents: (PGYI) Course Director and Instructor, PGYI, Introduction to Scholarship, 2008 - present; (PGY II) Lecture, “Second Generation Antipsychotic Medications,” 2005; Lecture, “Structured Diagnostic Instruments in Research and Clinical Practice,” 2006-present; Lecture, “Rating Scales in Research and Clinical Practice,” 2006-present; Lecture, “Selective Serotonin Reuptake Inhibitors,” 2006Lecture, “Dual Mechanism Antidepressants,” 2006; Lecture, “Antipsychotic Associated Weight Gain,” 2007; Lecture, “The Role of NeuroImaging in Research,” 2008-present; (PGYIII) Course Director and Instructor, PGYIII Tobacco Cessation, 2008-present; (PGYIV) Course Co-Director and Primary Instructor, PGYIV Psychiatry Advanced Psychopharmacology, 2004-present
Medical Student: (MS3) Inpatient Psychiatric Rotations, 1998-99; Consultation Liason Service, 1999-2000, 2008-present
Psychiatry Resident: (PGYI) Inpatient Psychiatric Services and Call, 2001-2005; (PGYII) Inpatient Psychiatric Services and Call, 2001-2005; Off ward Supervision, 2000-01, 2002-04; Consultation Liason Service, 2008-present; (PGYIII) Consultation Liason and Emergency Room Call, 2001-2005
Research Trainees: Neurosciences Graduate Student First Year Rotation, 2004; MS1 Scholarly Projects, 2007-present (3 students); Resident Research Track Experiences, 2006 – present (2 residents)
Course Director and Instructor, PGYI, Introduction to Scholarship, 2008 - present
Course Co-Director and Primary Instructor, PGYIV Psychiatry Advanced Psychopharmacology, 2004-present
Course Director and Instructor, PGYIII Tobacco Cessation, 2008-present
Associate Residency Training Director, Department of Psychiatry, 09/2008 – present
Attending Physician, State Mental Health Institute at Fort Logan, 2000-2001
Attending Physician, University of Colorado Hospital Inpatient Service, 07/2002-2008
Outpatient practice, University Physician’s Inc, 2004-present
Attending, University of Colorado Hospital Psychiatry Consultation-Liason Service, 01/2009-present
Clinical Director, Behavioral Health and Wellness Center, 01/2009-present
SCHOLARSHIPS AND PUBLICATIONS
Selected Peer-Reviewed Publications:
Martin LF, Kem WR and FreedmanR (2004). Alpha-7 Nicotinic Receptor Agonists: Potential New Candidates for the Treatment of Schizophrenia. Psychopharmacology 174: 54-64.
Harris JG, Kongs S, Allensworth D, Martin LF, Tregellas J, Sullivan B, Zerbe G and Freedman R (2004). Effects of Nicotine on Cognitive Deficits in Schizophrenia. Neuropsychopharmacology 29: 1378-1385.
Olincy A and Martin L (2005). Failure to inhibit the P50 auditory evoked potential in bipolar subjects with a history of psychosis. American Journal of Psychiatry 162 (1): 43-9.
Tregellas J, Tanabe JL, Martin LF and Freedman R (2005). fMRI of Response to Nicotine During a Smooth Pursuit Eye Movement Task in Schizophrenia. American Journal of Psychiatry 162 (2): 391-393.
Freedman R, Ross RG, Leonard S, Worsley M, Adams C, Waldo M, Tregellas J, Martin L, Olincy A, Tanabe J, Kisley M, Hunter S and Stevens K (2005). Early Biomarkers of Psychosis. Dialogues in Clinical Neuroscience 7(1): 17-29.
Tanabe J, Tregellas JR, Martin LF, Freedman R (2005). Effects of nicotine on hippocampal and cingulate activity during smooth pursuit eye movement in schizophrenia. Biological Psychiatry 59 (8): 754-761.
Ann Olincy; Josette G. Harris; Lynn L. Johnson; Vicki Pender; Susan Kongs; Diana Allensworth; Jamey Ellis; Gary O. Zerbe; Sherry Leonard; Karen E. Stevens; James O. Stevens; Laura Martin; Lawrence E. Adler; Ferenc Soti; William R. Kem; Robert Freedman (2006). Proof-of-Concept Trial of an 7 Nicotinic Agonist in Schizophrenia. Archives of General Psychiatry 63: 630-638.
Martin LF, Hall MH, Leonard S, Olincy A, Tregellas J, Freedman R (2007.) Sensory Gating and Alpha-7 Nicotinic Receptor Gene Allelic Variants in Schizoaffective Disorder, Bipolar Type. American Journal of Medical Genetics 144B: 611-14.
Martin LF, Olincy A, Hall MH, Ross R, Zerbe GO and Freedman R. (2007) The Neurophysiology of Schizophrenia, Bipolar Disorder and Schizoaffective Disorder. American Journal of Psychiatry 164 (12): 1900-6.
Tregellas JR, Shatti S, Tanabe JL, Martin LF, Gibson L, Wylie K, Freedman R, Rojas DC. (2007) Gray Matter Volume Differences and the Effects of Smoking on Gray Matter in Schizophrenia. Schizophrenia Research 97(1-3): 242-9.
Freedman R, Olincy A, Buchanan RW, Harris JG, Gold JM, Johnson L, Allensworth D, Guzman A, Clement B, Ball MP, Kutnick J, Pender V, Martin LF, Stevens KE, Wagner BD, Zerbe GO, Soti F and Kem WR. (2007) Initial Phase 2 Trial of a Nicotinic Agonist in Schizophrenia Am J Psychiatry. 2008; 165:1040-1047
Martin LF, Davalos DB and Kisley MA. The effects of nicotine on temporal processing as measured by the mismatch negativity waveform Nicotine & Tobacco Research, Volume 11, Number 6 (June 2009) 698–706.
Tegellas JR, Olincy A, Johnson L, Tanabe J, Shatti S, Martin LF, Singel D, Du Y, Soti F, Kem WR, Freedman R. Functional Magnetic Resonance Imaging of Effects of a Nicotinic Agonist in Schizophrenia. Neuropsychopharmacology (accepted 11/2009)
Grants and Contracts:
Research Career Development Award from the Department of Veterans Affairs for the nearly full time pursuit of medical research training funding full salary together with $20,000 annually for research, 1/8/06 to 1/7/09
Pfizer (Morris) “A Phase 3b 12-week, double-blind, placebo-controlled, multicenter study evaluating the safety and efficacy of varenicline tartrate (CP-526,555) 1mg BID for smoking cessation in subjects with schizophrenia and schizoaffective disorder, 01/09 – 12/09
Smoking Cessation and Clinical Symptoms in Schizophrenia; Principal Investigator; National Association for Research on Schizophrenia and Depression (NARSAD) Young Investigator Award; 07/2009-06/2011; 20% effort; $60,000